Literature DB >> 11787801

Direct process integration of cell disruption and fluidised bed adsorption in the recovery of labile microbial enzymes.

H Bierau1, R J Hinton, A Lyddiatt.   

Abstract

The practical feasibility and generic applicability of the direct integration of cell disruption by bead milling with the capture of intracellular products by fluidised bed adsorption has been demonstrated. Pilot-scale purification of the enzyme L-asparaginase from unclarified Erwinia chrysanthemi disruptates exploiting this novel approach yielded an interim product which rivalled or bettered that produced by the current commercial process employing discrete operations of alkaline lysis, centrifugal clarification and batch adsorption. In addition to improved yield and quality of product, the process time during primary stages of purification was greatly diminished. Two cation exchange adsorbents, CM HyperD LS (Biosepra/Life Technologies) and SP UpFront (custom made SP form of a prototype stainless steel/agarose matrix, UpFront Chromatography) were physically and biochemically evaluated for such direct product sequestration. Differences in performance with regard to product capacity and adsorption/desorption kinetics were demonstrated and are discussed with respect to the design of adsorbents for specific applications. In any purification of L-asparaginase (pI = 8.6), product-debris interactions commonly diminish the recovery of available product. It was demonstrated herein, that immediate disruptate exposure to a fluidised bed adsorbent promoted concomitant reduction of product in the liquid phase, which clearly counter-acted the product-debris interactions to the benefit of product yield.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11787801     DOI: 10.1023/a:1012054622066

Source DB:  PubMed          Journal:  Bioseparation        ISSN: 0923-179X


  1 in total

Review 1.  Quality Control and Downstream Processing of Therapeutic Enzymes.

Authors:  David Gervais
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.